Recent News

• 05.22.2025 - DiaMedica Therapeutics to Present at Jefferies Global Healthcare Conference 2025
• 05.19.2025 - DiaMedica Therapeutics Announces Key Opinion Leader Webinar on DM199 (Rinvecalinase Alfa) for the Treatment of Preeclampsia
• 05.14.2025 - DiaMedica Therapeutics Announces Poster Presentation at European Stroke Organisation Conference – ESOC 2025
• 05.13.2025 - DiaMedica Therapeutics Reports First Quarter 2025 Financial Results And Provides Business Highlights
• 05.08.2025 - DiaMedica Therapeutics to Participate in Upcoming Investor Conferences in May
• 05.07.2025 - DiaMedica Therapeutics to Report First Quarter 2025 Financial Results and Provide a Business Update May 14, 2025
• 03.17.2025 - DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2024 Financial Results
• 03.11.2025 - DiaMedica Therapeutics to Report Fourth Quarter 2024 Financial Results and Provide a Business Update March 18, 2025

Recent Filings

• 05.15.2025 - 8-K Current report
• 05.13.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 05.13.2025 - EX-99.1 EX-99.1
• 05.13.2025 - 8-K Current report
• 04.08.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.28.2025 - ARS Annual Report to Security Holders
• 03.28.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 03.28.2025 - DEF 14A Other definitive proxy statements
• 03.17.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.17.2025 - EX-99.1 EX-99.1